The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards
-
October 8, 2024
-
0 min
Clinical Report: Highlights from 50 Years of EBMT Van Bekkum Award Research
Overview
The European Society for Blood and Marrow Transplantation (EBMT) commemorated 50 years of pioneering research recognized by the Van Bekkum Award. Key advances include improved understanding and treatment of graft-versus-host disease, innovative gene and cellular therapies, and enhanced transplant outcomes in hematologic malignancies and immune disorders.
Background
The Van Bekkum Award honors outstanding contributions to hematopoietic stem cell transplantation and related fields. Over five decades, award recipients have advanced knowledge on immunological tolerance, gene marking, haploidentical transplantation, and cellular immunotherapy. Their work has shaped clinical practice in managing leukemia, graft-versus-host disease (GvHD), and transplant complications. The 50th Annual EBMT Conference highlighted these seminal studies, reflecting evolving strategies to improve patient survival and quality of life.
Data Highlights
| Year | Research Focus | Key Findings | Location |
|---|---|---|---|
| 1998 | Alloantigen specific anergy in T-cells | Preserved cytolytic activity against leukemia | Pavia, Italy |
| 2002 | Haploidentical SCT in AML | Survival advantage with KIR epitope incompatibility | Perugia, Italy |
| 2004 | NOD2/CARD15 mutations and GvHD | Association with GvHD and transplant-related mortality | Regensburg, Germany; Newcastle, UK; Vienna, Austria |
| 2010 | Defibrotide for hepatic VOD prevention | Reduced VOD incidence and complications in high-risk children | Multicenter European study |
| 2014 | CAR T-cell therapy targeting CD19 | Complete responses and long-term persistence without GvHD | Philadelphia, USA |
Key Findings
- Induction of alloantigen-specific anergy does not compromise leukemia-reactive T-cell cytotoxicity (1998).
- Haploidentical stem cell transplantation with KIR epitope incompatibility improves survival in high-risk AML patients (2002).
- NOD2/CARD15 gene mutations in donors and recipients correlate with increased graft-versus-host disease and transplant-related mortality (2004).
- Mesenchymal stem cells show promise in treating severe acute and chronic GvHD.
- Defibrotide effectively prevents hepatic veno-occlusive disease and related complications in pediatric high-risk patients (2010).
- Engineered T-cells, including CAR T-cells targeting CD19, demonstrate significant anti-leukemia activity with durable responses and minimal GvHD (2014).
Clinical Implications
These landmark studies underscore the importance of genetic and immunologic factors in transplant outcomes, guiding donor selection and post-transplant management. The advent of gene editing and cellular therapies offers new avenues for treating relapse and refractory disease while minimizing complications such as GvHD. Clinicians should consider integrating these advances into personalized transplant protocols to optimize patient prognosis.
Conclusion
The 50 years of Van Bekkum Award-winning research reflect transformative progress in hematopoietic stem cell transplantation, from fundamental immunology to cutting-edge cellular therapies. Continued innovation and collaboration remain essential to further improve survival and quality of life for transplant recipients.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
